Monte Rosa Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Monte Rosa completed enrollment and dosing for its GFORCE-1 Phase 1 study of MRT-8102 (NEK7-directed degrader) in elevated CVD risk subjects, with H2 2026 readout expected. The company activated MODeFIRE-1 Phase 2 study of MRT-2359 with apalutamide in mCRPC patients with AR mutations (~25 patients). Novartis activated Phase 2a/b study of MRT-6160 (VAV1-directed) in Sjögren's disease; Monte Rosa eligible for up to $2.1B in milestones and will co-fund Phase 3, sharing 30% of U.S. profits/losses and receiving tiered ex-U.S. royalties. Q2 2026 net loss was $43.4M vs. $12.3M in Q2 2025; cash position of $626.0M supports operations into 2029.
Why this rating
Multiple Phase 2 activations and Novartis milestone are meaningful, but Q2 net loss tripled YoY and collaboration revenue halved—offsetting catalysts. Cash runway adequate but burn rate rising. Moderate near-term significance for $212M market cap company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.